Victor M Moles1, Thomas Cascino2, Ashraf Saleh3, Krasimira Mikhova3, John J Lazarus2, Michael Ghannam2, Hong J Yun2, Matthew Konerman2, Richard L Weinberg2, Edward P Ficaro4, James R Corbett2,4, Vallerie V McLaughlin2, Venkatesh L Murthy2,4. 1. Division of Cardiovascular Medicine, Department of Internal Medicine and Frankel Cardiovascular Center, University of Michigan, 2nd Floor CVC / SPC 5853, 1500 E. Medical Center Dr.,, Ann Arbor, MI, 48109-5853, USA. vmoles@med.umich.edu. 2. Division of Cardiovascular Medicine, Department of Internal Medicine and Frankel Cardiovascular Center, University of Michigan, 2nd Floor CVC / SPC 5853, 1500 E. Medical Center Dr.,, Ann Arbor, MI, 48109-5853, USA. 3. Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 4. Division of Nuclear Medicine, Department of Radiology, University of Michigan, Ann Arbor, MI, USA.
Abstract
OBJECTIVES: We sought to determine the safety of regadenoson stress testing in patients with PH. BACKGROUND: PH is increasingly recognized at more advanced ages. As many as one-third of patients with PH have coronary artery disease. Because of their physical limitations, patients with PH are unable to adequately exercise. Regadenoson can potentially have an adverse impact due to their tenuous hemodynamics. Current guidelines suggest performing a coronary angiography in patients with PH who have angina or multiple coronary risk factors. METHODS: We identified 67 consecutive patients with confirmed PH by catheterization (mean PA > 25 mmHg not due to left heart disease) who underwent MPI with regadenoson stress. Medical records were reviewed to determine hemodynamic and ECG response to regadenoson. RESULTS: No serious events occurred. Common side effects related to regadenoson were observed, dyspnea being the most common (70.6%). No syncope occurred. Heart rate increased from 74.6 ± 14 to 96.3 ± 18.3 bpm, systolic blood pressure increased from 129.8 ± 20.9 to 131.8 ± 31 mmHg, and diastolic blood pressure decreased from 77.1 ± 11.4 to 72.9 ± 15.3 mmHg. There was no ventricular tachycardia, ventricular fibrillation, or second- or third-degree atrioventricular block. CONCLUSION: Regadenoson stress MPI appears to be well tolerated and safe in patients with PH.
OBJECTIVES: We sought to determine the safety of regadenoson stress testing in patients with PH. BACKGROUND: PH is increasingly recognized at more advanced ages. As many as one-third of patients with PH have coronary artery disease. Because of their physical limitations, patients with PH are unable to adequately exercise. Regadenoson can potentially have an adverse impact due to their tenuous hemodynamics. Current guidelines suggest performing a coronary angiography in patients with PH who have angina or multiple coronary risk factors. METHODS: We identified 67 consecutive patients with confirmed PH by catheterization (mean PA > 25 mmHg not due to left heart disease) who underwent MPI with regadenoson stress. Medical records were reviewed to determine hemodynamic and ECG response to regadenoson. RESULTS: No serious events occurred. Common side effects related to regadenoson were observed, dyspnea being the most common (70.6%). No syncope occurred. Heart rate increased from 74.6 ± 14 to 96.3 ± 18.3 bpm, systolic blood pressure increased from 129.8 ± 20.9 to 131.8 ± 31 mmHg, and diastolic blood pressure decreased from 77.1 ± 11.4 to 72.9 ± 15.3 mmHg. There was no ventricular tachycardia, ventricular fibrillation, or second- or third-degree atrioventricular block. CONCLUSION:Regadenoson stress MPI appears to be well tolerated and safe in patients with PH.
Authors: Raymond J Gibbons; Gary J Balady; J Timothy Bricker; Bernard R Chaitman; Gerald F Fletcher; Victor F Froelicher; Daniel B Mark; Ben D McCallister; Aryan N Mooss; Michael G O'Reilly; William L Winters; Raymond J Gibbons; Elliott M Antman; Joseph S Alpert; David P Faxon; Valentin Fuster; Gabriel Gregoratos; Loren F Hiratzka; Alice K Jacobs; Richard O Russell; Sidney C Smith Journal: J Am Coll Cardiol Date: 2002-10-16 Impact factor: 24.094
Authors: Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper Journal: Eur Respir J Date: 2015-08-29 Impact factor: 16.671
Authors: Robert C Hendel; Daniel S Berman; Marcelo F Di Carli; Paul A Heidenreich; Robert E Henkin; Patricia A Pellikka; Gerald M Pohost; Kim A Williams Journal: J Am Coll Cardiol Date: 2009-06-09 Impact factor: 24.094
Authors: Avi Shimony; Mark Jeffrey Eisenberg; Lawrence Glenn Rudski; Robert Schlesinger; Jonathan Afilalo; Dominique Joyal; Leonidas Dragatakis; Andrew Hirsch; Kim Boutet; Benjamin Daniel Fox; David Langleben Journal: Am J Cardiol Date: 2011-05-19 Impact factor: 2.778
Authors: Carlos Salgado Garcia; Carlos Salgado Garcia; Amelia Jimenez Heffernan; Amelia Jimenez Heffernan; Elena Sanchez de Mora; Carlos Ramos Font; Juana Lopez Martin; Francisco Rivera de los Santos; Ignacio Ynfante Milá Journal: Eur J Nucl Med Mol Imaging Date: 2013-07-16 Impact factor: 9.236
Authors: David B Badesch; Gary E Raskob; C Greg Elliott; Abby M Krichman; Harrison W Farber; Adaani E Frost; Robyn J Barst; Raymond L Benza; Theodore G Liou; Michelle Turner; Scott Giles; Kathy Feldkircher; Dave P Miller; Michael D McGoon Journal: Chest Date: 2009-10-16 Impact factor: 9.410
Authors: Christian F Opitz; Marius M Hoeper; J Simon R Gibbs; Harald Kaemmerer; Joanna Pepke-Zaba; J Gerry Coghlan; Laura Scelsi; Michele D'Alto; Karen M Olsson; Silvia Ulrich; Werner Scholtz; Uwe Schulz; Ekkehard Grünig; Carmine D Vizza; Gerd Staehler; Leonhard Bruch; Doerte Huscher; David Pittrow; Stephan Rosenkranz Journal: J Am Coll Cardiol Date: 2016-07-26 Impact factor: 24.094
Authors: S Rich; D R Dantzker; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; S K Koerner Journal: Ann Intern Med Date: 1987-08 Impact factor: 25.391
Authors: Edmund M T Lau; Rebecca R Vanderpool; Preeti Choudhary; Lisa R Simmons; Tamera J Corte; Paola Argiento; Michele D'Alto; Robert Naeije; David S Celermajer Journal: Chest Date: 2014-10 Impact factor: 9.410